SCHEMBL2245397

SCHEMBL2245397

O=C(O)CC[C@H](NC(=O)c1ccc(-c2ccccc2)cc1)C(=O)NCCCCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FOLH1 Q04609 2/20 0.59
L3MBTL1 Q9Y468 1/20 0.57
ADAMTS5 Q9UNA0 2/20 0.56
ADAMTS4 O75173 1/20 0.56
MMP2 P08253 1/20 0.53
MMP8 P22894 1/20 0.53
MMP12 P39900 1/20 0.53
CCKBR P32239 1/20 0.53
PTAFR P25105 1/20 0.53
KDM1A O60341 1/20 0.52
MAOA P21397 1/20 0.52
HSP90AA1 P07900 1/20 0.51
CTSB P07858 1/20 0.51
CTSS P25774 1/20 0.51
CTSK P43235 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2246518 0.97 L3MBTL1 (0.58) FOLH1L3MBTL1ADAMTS5ADAMTS4MMP2
SCHEMBL2246984 0.92 L3MBTL1 (0.60) FOLH1L3MBTL1ADAMTS5ADAMTS4MMP2
SCHEMBL2245074 0.90 ADAMTS5 (0.60) FOLH1L3MBTL1ADAMTS5ADAMTS4MMP2
SCHEMBL2249268 0.88 ADAMTS5 (0.58) FOLH1L3MBTL1ADAMTS5ADAMTS4MMP2
SCHEMBL2250028 0.87 ADAMTS5 (0.57) FOLH1L3MBTL1ADAMTS5ADAMTS4MMP2
SCHEMBL2244204 0.87 L3MBTL1 (0.61) FOLH1L3MBTL1ADAMTS5ADAMTS4MMP2
SCHEMBL2245808 0.87 ADAMTS5 (0.57) FOLH1L3MBTL1ADAMTS5ADAMTS4MMP2
SCHEMBL2244966 0.86 L3MBTL1 (0.60) FOLH1L3MBTL1ADAMTS5ADAMTS4MMP2
SCHEMBL2247187 0.86 L3MBTL1 (0.60) FOLH1L3MBTL1ADAMTS5ADAMTS4MMP2
SCHEMBL2250363 0.86 L3MBTL1 (0.62) FOLH1L3MBTL1ADAMTS5ADAMTS4MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US claimed
US-7998965-B2 Glutamate aggrecanase inhibitors WYETH LLC (US) 2011-08-16 US disclosed
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2010-01-14 US disclosed
US-7553873-B2 Glutamate aggrecanase inhibitors WYETH (US) 2009-06-30 US disclosed
EP-1902014-A2 GLUTAMATE AGGRECANASE INHIBITORS Wyeth (US) 2008-03-26 EP disclosed
US-20070043066-A1 Glutamate aggrecanase inhibitors WYETH (US) 2007-02-22 US disclosed
WO-2007008994-A2 GLUTAMATE AGGRECANASE INHIBITORS WYETH (US) 2007-01-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100010012-A1 GLUTAMATE AGGRECANASE INHIBITORS ADAMTS5, ADAMTS1, ADAMTS7 FOLH1 17/4885L3MBTL1 4308/4885ADAMTS5 1/4885
US-20070043066-A1 Glutamate aggrecanase inhibitors ADAMTS5, ADAMTS1, ADAMTS7 FOLH1 17/4885L3MBTL1 4308/4885ADAMTS5 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.